Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains.
Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains.
复制标题
DOI：
10.7554/elife.69317
复制
发表时间：
2021-07-29
期刊：
影响因子：
7.7
通讯作者：
Kassiotis G
中科院分区：
文献类型：
--
作者：
Faulkner N;Ng KW;Wu MY;Harvey R;Margaritis M;Paraskevopoulou S;Houlihan C;Hussain S;Greco M;Bolland W;Warchal S;Heaney J;Rickman H;Spyer M;Frampton D;Byott M;de Oliveira T;Sigal A;Kjaer S;Swanton C;Gandhi S;Beale R;Gamblin SJ;McCauley JW;Daniels RS;Howell M;Bauer D;Nastouli E;Kassiotis G
严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）毒株诱导的异型免疫的程度是新出现的变异体传播和疫苗接种活动成功的主要决定因素，但仍不完全清楚。我们检测了SARS-CoV-2变异体B.1.1.7（Alpha）的免疫原性，该变异体在英国出现并在全球传播。我们测定了B.1.1.7感染诱导的刺突糖蛋白结合抗体和真实病毒中和抗体的滴度，以推断同型和异型免疫。B.1.1.7感染引起的抗体对亲本菌株或南非变异株B.1.351（Beta）的识别和中和作用显著低于感染变异株。B.1.1.7感染后交叉反应性的下降比亲本菌株感染后显著更明显。结果表明SARS-CoV-2变异株诱导的异型免疫是不对称的。这项工作得到了弗朗西斯克里克研究所和马格德堡马格德堡的马克斯普朗克复杂技术系统动力学研究所的支持。
The degree of heterotypic immunity induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains is a major determinant of the spread of emerging variants and the success of vaccination campaigns, but remains incompletely understood. We examined the immunogenicity of SARS-CoV-2 variant B.1.1.7 (Alpha) that arose in the United Kingdom and spread globally. We determined titres of spike glycoprotein-binding antibodies and authentic virus neutralising antibodies induced by B.1.1.7 infection to infer homotypic and heterotypic immunity. Antibodies elicited by B.1.1.7 infection exhibited significantly reduced recognition and neutralisation of parental strains or of the South Africa variant B.1.351 (Beta) than of the infecting variant. The drop in cross-reactivity was significantly more pronounced following B.1.1.7 than parental strain infection. The results indicate that heterotypic immunity induced by SARS-CoV-2 variants is asymmetric. This work was supported by the Francis Crick Institute and the Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg.